Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
dc.authorid | Artac, Mehmet/0000-0003-2335-3354 | |
dc.authorid | Paksoy, Nail/0000-0003-4636-2595 | |
dc.authorwosid | Artac, Mehmet/AAF-8158-2020 | |
dc.authorwosid | Sendur, Mehmet Ali Nahit/H-7555-2014 | |
dc.authorwosid | Coşkun, Hasan Şenol/C-2070-2016 | |
dc.authorwosid | Paksoy, Nail/HKF-3015-2023 | |
dc.contributor.author | Tural, Deniz | |
dc.contributor.author | Olmez, Omer Fatih | |
dc.contributor.author | Sumbul, Ahmet Taner | |
dc.contributor.author | Artac, Mehmet | |
dc.contributor.author | Ozhan, Nail | |
dc.contributor.author | Akar, Emre | |
dc.contributor.author | Cakar, Burcu | |
dc.date.accessioned | 2024-06-12T11:22:28Z | |
dc.date.available | 2024-06-12T11:22:28Z | |
dc.date.issued | 2021 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description | ASCO Genitourinary Cancers Symposium (GU ASCO) -- FEB 11-13, 2021 -- ELECTR NETWORK | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | ASCO | en_US |
dc.identifier.doi | 10.1200/JCO.2021.39.6_suppl.409 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.issue | 6 | en_US |
dc.identifier.uri | https://doi.org/10.1200/JCO.2021.39.6_suppl.409 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/25945 | |
dc.identifier.volume | 39 | en_US |
dc.identifier.wos | WOS:000636801500412 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.ispartof | Journal Of Clinical Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma. | en_US |
dc.type | Conference Object | en_US |